Impact of ASCO/CAP 2007, 2013 and 2018 recommendations on Her-2/neu gene amplification status testing in patients with breast cancer
Aim. To Assess the significance of changes in the diagnostics of Her-2/neu gene amplification status using the ASCO/CAP 2007, 2013 and 2018 recommendations by retrospective evaluation of breast cancer (BC) tissue test results performed by fluorescence in situ hybridization (FISH). Methods. Her-2/neu FISH dual probe test data of 797 BC specimens were re-evaluated in accordance with the requirements of the consecutive updated ASCO/CAP recommendations. Results. The proportion of cases without Her-2/neu gene amplification by the ASCO/CAP 2013 and 2018 criteria was 11,0 % lower than by the 2007 ASCO/CAP criteria. There was no statistically significant difference between the number of Her-2/neu gene amplification positive cases according to ASCO/CAP 2007, 2013 and 2018 criteria. The proportion of cases with a doubtful outcome for the use of ASCO/CAP in 2018 was significantly higher (12,2 %, p < 0,01) compared to that by ASCO/CAP 2007 and 2013 (6,6 % and 12,2 % accordingly). Conclusions. The findings of a re-benchmarking review (in accordance with the 2018 ASCO/CAP criteria) of the FISH case study results show practical differences from the previous ASCO/CAP 2007, 2013 recommendations. The proportion of samples, which needs the additional research, increases with each revision of the recommendations against the backdrop of the expansion of the case group with questionable amplification status of the Her-2/neu gene by the FISH double probe method.
Keywords: ASCO/CAP, amplification status of the gene Her-2/neu, breast cancer.
Ballard M., Jalikis F., Krings G., et al. «Nonclassical» HER2 FISH results in breast cancer: A multi-institutional study. Mod Pathol. 2017. Vol. 30. Р. 227–235. doi: 10.1038/modpathol.2016.175.
Beaty В., Mai S., Squire J. FISH: a practical approach, Practical approach series. Oxford, Oxford University Press, 2002. P. 100–102.
Buzdar A. U., Ibrahim, N. K., Francis, D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of clinical oncology. 2005. Vol. 23(16). P. 3676– 3685. doi: 10.1200/JCO.2005.07.032.
de Melo Gagliato D., Jardim, D. L. F., Marchesi M. S. P., Hortobagyi, G. N. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016. Vol. 7(39), P. 64431. doi: 10.18632/oncotarget.7043.
Fan Yao-Shan, et al. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast cancer research and treatment. 2016. Vol. 155.3. P. 457– 462. doi: 10.1007/s10549-016-3717-z.
Lim T. H., Lim, A. S. T., Thike A. A. et al. Implications of the updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations on human epidermal growth factor receptor 2 gene testing using immunohistochemistry and fluorescence in situ hybridization for breast cancer. Archives of pathology & laboratory medicine. 2016. Vol. 140(2), P. 140–147. doi: 10.5858/arpa.2015-0108-OA.
Loibl Sibylle, and Luca Gianni. HER2-positive breast cancer. The Lancet. 2017. Vol. 389.10087. P. 2415– 2429. doi: 10.1016/S0140-6736(16)32417-5.
McKeage K., & Perry, C. M. Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2. American Journal of Cancer. 2002. Vol. 1(3), P. 217–221. doi: 10.2165/00024669-200201030- 00006.
Press M. F., Villalobos I., Santiago A. et al. Assessing the new American Society of Clinical Oncology/Collegeof American Pathologists guidelines for HER2 testing by fluorescence in situ hybridization: Experience of an academic consultation practice. Arch Pathol Lab Med. 2016a. Vol. 140. P. 1250– 1258. doi: 10.5858/arpa.2016-0009-OA.
Press Michael F., et al. HER2 gene amplification testing by fluorescent in situ hybridization (FISH): Comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. Journal of Clinical Oncology. 2016b. Vol. 34.29. P. 3518. doi: 10.1200/JCO.2016.66.6693.
Shah Mithun Vinod, et al. Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. Journal of Clinical Oncology. 2014. P. 523–523. doi: 10.1200/ jco.2014.32.15_suppl.523.
Wolff Antonio C., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Archives of pathology & laboratory medicine. 2018. Vol. 142.11. P. 1364–1382. doi: 10.5858/arpa.2018-0902-SA.
Wolff Antonio C., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology and Laboratory Medicine. 2013. Vol. 138.2. P. 241–256. doi: 10.5858/arpa.2018-0902-SA.
Klimuk B.T. et al. Results of mutation status gene HER-2/NEU in patients with breast cancer in Ukraine. Fakt. eksp. evol. org. 2017. Vol. 21. P. 321–324.